PAIOF (Paion AG) Quick Ratio: 0.51 (As of Jun. 2023)


PAIOF Paion AG PAIOF
10 GF Score
Price $0.01
View Full Analysis

What is Paion AG Quick Ratio?

Paion AG PAIOF +9,900.00% 10 Quick Ratio is 0.51 as of Jun. 2023. GuruFocus rates PAIOF with a GF Score™ of 10/100.

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Paion AG's quick ratio for the quarter that ended in Jun. 2023 was 0.51.

Paion AG has a quick ratio of 0.51. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Paion AG's Quick Ratio or its related term are showing as below:

PAIOF's Quick Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.45
* Ranked among companies with meaningful Quick Ratio only.

Paion AG  (OTCPK:PAIOF) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Paion AG Quick Ratio Related Terms


Paion AG Quick Ratio Historical Data

* Premium members only.

The historical data trend for Paion AG's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paion AG Quick Ratio Chart

Paion AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.29 2.23 3.70 1.04 1.12

Paion AG Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.72 1.04 2.15 1.12 0.51

PAIOF vs ZTS, NBIX, VTRS: Quick Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Paion AG's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paion AG Quick Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Paion AG's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Paion AG's Quick Ratio falls into.


PAIOF
10GF Score
Paion AG PAIOF
Quick Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paion AG Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Paion AG's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Quick Ratio (A: Dec. 2022 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(18.891-3.941)/13.364
=1.12

Paion AG's Quick Ratio for the quarter that ended in Jun. 2023 is calculated as

Quick Ratio (Q: Jun. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(13.885-4.641)/18.205
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Quick Ratio →
What does a Quick Ratio of 0.51 mean?
Paion AG (PAIOF) has a Quick Ratio of 0.51 as of Jun. 2023. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Paion AG and its competitors.
Is Paion AG's Quick Ratio too high?
Paion AG's current Quick Ratio is 0.51. The Drug Manufacturers industry median Quick Ratio is 1.45. Paion AG's value of 0.51 is 64.8% below this industry median. Overall, Paion AG has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Paion AG's Quick Ratio compare to ZTS and NBIX?
Paion AG's Quick Ratio of 0.51 can be compared against companies in the Drug Manufacturers industry. The industry median Quick Ratio is 1.45. Paion AG's value of 0.51 is 64.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paion AG's current Quick Ratio of 0.51 is 64.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Paion AG and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paion AG's current Quick Ratio is 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paion AG stock overvalued right now?
Paion AG (PAIOF) has a current Quick Ratio of 0.51. The current Quick Ratio is 0.51 and 64.8% below the Drug Manufacturers industry median of 1.45. Paion AG's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Paion AG (PAIOF), the current Quick Ratio is 0.51 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paion AG Business Description

Address Heussstrasse 25, Aachen, DEU, 52078
Paion AG is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
10GF Score

Get the complete analysis for PAIOF

Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price